## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Germeyer, S. et al U.S. Appln. No. : To be assigned Confirmation No. : To be assigned U.S. Filing Date : February 5, 2004 Title of Invention : Fluorenecarboxylic Acid E and use Thereof as Medica Attny. Docket No. : 1/1292-1-C1US		1625 Charanjit Aulakh he Manufacture Thereof,
Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
February 5, 2004		
TRANSMITTAL LETTER FOR INFOR	MATION DISCL	OSURE STATEMENT
Sir:		
Transmitted herewith concerning the subject ap Statement (Form 1449A/B) under 37 C.F.R. §§ hereinbelow.	plication is an Info 1.56 and 1.97, as n	ormation Disclosure nore specifically described
1.97(b). This Statement is being f date of a national application other than a contin §1.53 (d); ii) within three (3) months of the date 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114.	nued prosecution a e of entry of the na e; iii) before the ma t Office action afte	pplication under 33 C.F.R. tional stage as set forth in ailing of a first Office action
1.97(c). This Statement is being for C.F.R. §1.97(b), but before the mailing date of: notice of allowance under 37 C.F.R. §1.311, or in the application. This Statement is being account.	i) a final action uniii) an action that o	der 37 C.F.R. §1.113, ii) a
A statement as specified in 37 C	C.F.R. §1.97(e) [see	e below]; or
The fee set forth in 37 C F P &1	17(n)	

		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e	).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a expart foreign application not more than three (3) months prior to the filing of that information disclosure statement; or
	foreign makin inform §1.56(	No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after greasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 C.F.R. (c) more than three (3) months prior to the filing of the instant information sure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte n secti	rpart ap	d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying is closure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

## **REMARKS**

The cited references can be located in the parent application filed January 2, 2003 and accorded Serial Number 10/335,795.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski Attorney for Applicant(s)

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4868

Express Mail Label No.: EV 368945333US

Deposit Date: February 5, 2004

I HEREBY CERTIFY THAT THE ABOVE PAPERS AND FEE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS

ADDRESSED TO:

MAIL STOP PATENT APPLICATION

Commissioner For Patents

P. O. Box 1450 Alexandria, VA 2

Timethy V. Witkowski Peg. No. 40 232

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number To be assigned Filing Date INFORMATION DISCLOSURE February 5, 2004 First Named Inventor Germeyer, S. et al STATEMENT BY APPLICANT Art Unit 1625 **Examiner Name** Charanjit Aulakh (Use as many sheets as necessary) Attorney Docket Number 1/1292-1-C1US

	-		U. S. PAT	FNT D	OCUM	FNTS			_
Examiner nitials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (# known)</sup>	Publication D MM-DD-YY	Date	Na	ame of Patentee or ant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	÷ it
		US-				**************************************			•
		US-							
		US-							
		US-							
	-	US-	WOLLDEN TO THE TOTAL TOT	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		CONTROL CONTROL CAMBRE CONTROL OF MAN AND		1900 - 19	***
		US-							
		US-						,	
		US-	······································						_
		US-							_
		US-					***************************************		
		US-				ner is william or will remain the control of the co			
		US-		***************************************					,
		US-							_
		US-			- n				
		US-							-
		US-							_
		US-					· <del></del>		••••
***************************************		US-			······································		) <del></del>		
			FOREIGN P	ATENT	DOCL	JMENTS		<del>-</del>	Ξ
Examiner	Cite	Foreign Patent Docum	Ī	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines,	
	No.1	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# ki						Where Relevant Passages or Relevant Figures Appear	
		WO 92/16528		10/01/1	992	BIKG		, , , , , , , , , , , , , , , , , , ,	
	••••••				••••••		••••••		•••

FOREIGN FATENT DOCUMENTS								
Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>			
	WO 92/16528	10/01/1992	BIKG					
	No.1	Cite No.1 Country Code <sup>3</sup> Number <sup>4</sup> 'Kind Code <sup>5</sup> (# known)  WO 92/16528	Cite No.   Foreign Patent Document	Cite No. 1 Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document  WO 92/16528 10/01/1992 BI KG	Cite No. 1 Foreign Patent Document Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Passages or Relevant Passages or Relevant Figures Appear 10/01/1992 BI KG			

Examiner	Date	1
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.usr/to.gov">www.usr/to.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Transation is adactived.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for t	form 1449B/PTO		- ·	Complete if Known				
					Application Number	To be assigned			
	INFOR	RMATION E	DISCLOS	SURE	Filing Date	February 5, 2004			
STATEMENT BY APPLICANT				CANT	First Named Inventor	Germeyer, S. et al			
					Art Unit	1625	-		
	(	Use as many sheets	as necessary)		Examiner Name	Charanjit Aulakh			
	Sheet	2	of	2	Attorney Docket Number	1/1292-1-C1US			

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
		Bowden, Keith et al; Structure-activity relations. I. Series of antagonists of acetylcholine and histaruine at the postganglionic receptors, Journal of Medicinal Chemistry (1970), 13(2), 225-30, XP000960623						
		Stubbins, James F. et al; Muscarinic M1 and M2 binding affinity of cyclic amine derivatives of caramiphen and dicyclomine; Medicinal Chemistry Research (1992), 2(6), 384-93 XP009011390						
		Albanus, Lennart; Central and peripheral effects of anticholinergic compounds; ACTA Pharmacologica et Toxicologica (1970), 28(4), 305-26, XP009011388						
		Farquharson, Muriel, et al; Antagonism of the effects of tremorine by tropine derivatives, Brit. J. Pharmacol. (1959), 14, 559-66, XP009011410						
		Meyerhoffer, Anita et al; Acid-base properties of atropine, scopolamine and some glycolic acid esters; ACTA Chemica Scandinavica (1947-1973), (1973), 27(3), 868-74, XP009011391						
	į							

$\overline{}$			
Examiner		Date	
Signature	·	Considered	<u> </u>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.